Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents falls 51.0% from a year ago

Cash & equivalents stood at $27.85M at the end of Q3 FY2026, down 51.0% from a year earlier and down 48.7% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.

Context

  • Cash & equivalents amounted to 9.0% of total assets at the end of Q3 FY2026, down 19.6 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -51.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$27.85M-48.7% QoQ
Last fiscal yearDec 2025
$18.91M-44.5% YoY
Year agoSep 2025
$56.87M-51.0% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-51.0%——
1 year-44.5%——
3-year CAGR+14.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
18.91M USD
Year-over-year change
-44.5%
4-year CAGR
-15.3%

Cash & Equivalents vs competitors

How TRVI compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -51.0% is the lowest of 8, against a peer median of +35.6%.
  • Cash & equivalents amounts to 9.0% of total assets for TRVI, versus a peer median of 50.3%.
TRVI Competitors
Cash & Equivalents for TRVI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ACADACADIA Pharmaceuticals Inc.Sep 2026$976.45M USD+278.5%+15.7%54.4%
TBPHTheravance Biopharma, Inc.Mar 2026$288.1M USD+160.5%-17.4%61.0%
LQDALiquidia CorporationJun 2026$284.18M USD+63.9%+26.9%54.4%
TENXTenax Therapeutics, Inc.Mar 2026$118.76M USD+6.6%+258.2%96.4%
UPBUpstream Bio, Inc.Mar 2026$96.72M USD+35.6%+81.3%30.4%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$78.06M USD+35.5%+19.1%15.7%
VCREVicore Pharma Holding ABJun 2026SEK 44.2M SEK——46.1%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$38.09M USD-39.4%-9.5%14.2%
TRVITrevi Therapeutics, Inc.Sep 2026$27.85M USD-51.0%+14.5%9.0%
Peer median (excluding TRVI) —+35.6%+19.1%50.3%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents36.83M12.59M32.4M34.1M18.91M
Short-term Investments0107.92M50.57M73.53M169.35M
Net Receivables241K00532K986K
Inventory00000
Other Current Assets01.31M955K335K1.15M
Total Current Assets37.96M122.62M87.55M109.43M191.66M
Property, Plant & Equipment (Net)184K194K1.56M1.23M855K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets334K205K297K243K928K
Total Non-current Assets518K399K1.86M1.47M1.78M
Total Assets38.48M123.02M89.4M110.9M193.44M
Account Payables2.85M2.86M1.81M3.41M3.91M
Short-term Debt5.83M7M000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities114K1.51M1.61M2.54M2.75M
Total Current Liabilities12.72M13.4M5.82M10.51M9.75M
Long-term Debt8.65M2.15M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities03K000
Total Non-current Liabilities8.68M2.16M1.03M747K446K
Total Liabilities21.4M15.56M6.86M11.26M10.2M
Common Stock29K60K68K94K128K
Retained Earnings(180.92M)(210.07M)(239.13M)(287.05M)(329.8M)
Accumulated OCI0(122K)(29K)61K148K
Other Stockholders Equity00000
Minority Interest00000
Total Equity17.08M107.46M82.55M99.64M183.24M
Total Debt14.63M9.18M1.34M1.03M753K
Net Debt(22.2M)(3.41M)(31.06M)(33.07M)(18.16M)

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.